Skip to content
Precision for Medicine
patient-recruitement-2 patient-recruitement-mobile-2

Patient Recruitment Strategies

Finding the right patients for your trial can be challenging, especially when affected populations are small, such as for rare disease trials. Contact Us
Precision’s holistic patient recruitment approach leverages our global reach, extensive network of disease researchers, and patient advocacy groups to assemble a strategy to match the patient to your clinical trial based on your study’s criteria. For targeted therapeutics, we use biomarker-driven screening to find the patients expected to respond to your therapeutic, moving quickly and with confidence in data quality thanks to our in-house specialty lab services.

Smart patient recruitment strategies

Our network spans the globe, just like your patients do

patient_rec_img

Building relationships with communities and specialists

Patient advocacy group relationships and social media outreach help reach into affected communities.

Meanwhile, our established relationships with key opinion leaders and clinical research sites around the globe secure access to a wide range of patient populations.

Case Study: Enrolling a global natural history study: How to find 200 rare patients

A sponsor selected Precision to manage a global natural history study in a rare, X-linked kidney disorder. The study had been recommended by the FDA because there was extremely limited published data on this rare disease—the goal was to characterize renal function and decline in patients with the disease prior to initiating a phase 2/3 clinical study. The study, to be conducted in the United States, Canada, Australia and in Europe, would follow 200+ patients for approximately 2 years.

Enrollment was by far the greatest study challenge, combining a low disease prevalence and a primary target population—young males—with life commitments such as school and work that left little time for participation in a trial that offered no therapeutic benefit for participants and would require traveling to a clinic every 3 to 6 months.

Read the latest insights on Precision’s blog

Discover expert analysis and broaden your understanding through Precision’s Insights on current research, case studies, and trends. 

Read: FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know

Clinical Trials - Regulatory - Oncology

FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1757700176991, hs_published_at=1757700235512, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=1000,height=1000,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/John%20McIntyre.jpg',altText='John McIntyre',fileId=195809756215}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=26433386}, second={hs_id=195804116749, hs_child_table_id=0, hs_updated_at=1757598950007, hs_published_at=1757700235512, description=An expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2. Possesses a profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies, bispecifics and T-cell engagers. Spearheaded initiatives to develop novel endpoints in blood cancer such as minimal residual disease (MRD) in lymphoma and chronic lymphocytic leukemia (CLL.), avatar=Image{width=1000,height=1000,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Nick%20Richardson.jpg',altText='Nick Richardson',fileId=195807970451}, linkedin=https://www.linkedin.com/in/nicholas-richardson-do-mph-049784113/, lastname=Richardson, DO, MPH, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757516077087, hs_is_edited=false, hs_deleted_at=0, name=Nick, job=Vice President, Clinical Development, slug=nick-richardson, hs_updated_by_user_id=26433386}, third={}})
  • John M. avatar

    John M.

  • Nick R. avatar

    Nick R.

Discover
Read: How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development

Translational Research - Biomarkers - Oncology

How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1757700235512, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1757516479594, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale

Discover
Read: Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

Early Phase Research - Gene Therapies

Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1757700235512, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover